Stockpiled Ebola vaccines trigger antibody response against Bundibugyo virus in lab tests
Lab tests indicate that vaccines originally developed for the Zaire ebolavirus can trigger an immune response against the Bundibugyo virus. This finding suggests a potential pathway for protecting populations against the ongoing outbreak in Central Africa.
Why it matters
Repurposing existing vaccines could provide a faster, more cost-effective solution to managing outbreaks of related viral strains where no specific vaccine exists.
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Zaire ebolavirus vaccine regimens produced antibodies that recognized Bundibugyo virus. Credit: Pexels. A highly contagious Ebola virus species, Bundibugyo virus (BDBV), has driven several outbreaks since 2007, including the ongoing outbreak in the Democratic Republic of Congo and Uganda in 2026. Bundibugyo virus causes severe viral hemorrhagic fever that affects multiple organ systems, damages blood vessels and can progress to severe symptoms, including bleeding and shock. Because there was no licensed vaccine designed specifically for the virus, researchers wanted to know whether vaccines already used for the more common Zaire ebolavirus could be repurposed to help protect people against Bundibugyo virus.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in